International journal of cancer
Neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 versus oxaliplatin and S-1 for locally advanced gastric adenocarcinoma: A multicenter, real-world cohort study.
Peng Jin, Xu Liu, Guoliang Zheng, Zhi Zheng, Haikuo Wang, Xinxin Shao, Yujuan Jiang, Wangyao Li, Haitao Hu, Yiming Lu, Peng Wang, Quan Xu, Yantao Tian
Published: 202510.1002/ijc.70315
Abstract
Although phase II trials have shown that adding docetaxel to S-1/oxaliplatin (DOS) improves pathological response in HER2-negative locally advanced gastric cancer (LAGC), robust real-world evidence comparing DOS with the standard S-1/oxaliplatin (SOX…
Preview only. Read the full abstract at the source